<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788125</url>
  </required_header>
  <id_info>
    <org_study_id>07053</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-07053</secondary_id>
    <secondary_id>CA180 121</secondary_id>
    <secondary_id>CDR0000617760</secondary_id>
    <nct_id>NCT00788125</nct_id>
  </id_info>
  <brief_title>Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors</brief_title>
  <official_title>Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and&#xD;
      etoposide, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving dasatinib together with ifosfamide,&#xD;
      carboplatin, and etoposide may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of dasatinib when&#xD;
      given together with ifosfamide, carboplatin, and etoposide and to see how well they work in&#xD;
      treating young patients with metastatic or recurrent malignant solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerated dose (MTD) of dasatinib when given immediately&#xD;
           following ifosfamide, carboplatin, and etoposide phosphate (D-ICE) as a re-induction&#xD;
           regimen in young patients with metastatic or recurrent malignant solid tumors. (Phase I)&#xD;
&#xD;
        -  To describe and define the toxicities of D-ICE in these patients. (Phase I)&#xD;
&#xD;
        -  To determine the safety and feasibility of prolonged administration of single-agent&#xD;
           dasatinib following completion of 2-6 courses of D-ICE in these patients. (Phase I)&#xD;
&#xD;
        -  To estimate the overall survival, progression-free survival, and time to progression in&#xD;
           patients treated with D-ICE at the MTD followed by single-agent dasatinib. (Phase II)&#xD;
&#xD;
        -  To estimate the response rate to two courses of D-ICE when given at the MTD in these&#xD;
           patients. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the phosphotyrosine state of SRC family kinases and related signaling&#xD;
           pathways, including FAK, STAT3, VEGFR, AKT, EGFR, KIT, EPHA2, and PDGFR, in&#xD;
           paraffin-embedded tumor samples as measured by immunohistochemistry prior to and during&#xD;
           treatment with dasatinib.&#xD;
&#xD;
        -  To assess gene expression profiling in fresh frozen tissue samples as measured by&#xD;
           microarray analysis (Affymetrix GeneChips) at baseline to identify molecular signatures&#xD;
           that may predict response to dasatinib.&#xD;
&#xD;
        -  To correlate biomarkers and molecular signatures with dasatinib dosage, toxicity, and&#xD;
           antitumor activity.&#xD;
&#xD;
        -  To evaluate the effect of dasatinib on phosphorylation of SRC family kinases in&#xD;
           peripheral blood mononuclear cell samples as a surrogate marker of response prior to&#xD;
           treatment with dasatinib, at days 14-21 or when WBC ≥ 500/μL, during each treatment&#xD;
           course, at the time of local control, and at the time of progression.&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I, dose-escalation study of dasatinib followed by a&#xD;
      phase II study. Patients enrolled in phase II are stratified according to disease.&#xD;
&#xD;
      Patients receive D-ICE comprising oral dasatinib twice daily on days 5-21, ifosfamide IV over&#xD;
      1 hour and etoposide phosphate IV over 1 hour on days 1-5, and carboplatin IV over 1 hour on&#xD;
      days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients then undergo radiotherapy and/or surgery&#xD;
      (consolidation therapy) after 2, 4, or 6 courses of D-ICE. After completion of consolidation&#xD;
      therapy, patients receive oral dasatinib twice daily for up to 6 months in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Tumor tissue and peripheral blood mononuclear cell (PBMC) samples are collected periodically&#xD;
      for correlative laboratory studies. PBMCs are analyzed by western blotting for total and&#xD;
      phospho-SRC, phospho-FAK, and other relevant biomarkers. Tumor tissue samples are analyzed by&#xD;
      IHC for total and phospho-SRC, phospho-FAK, phospho-STAT3, phospho-KIT, and phospho-PDGFR,&#xD;
      EPHA2, and VEGF. Tumor tissue samples are also analyzed by microarray gene expression&#xD;
      profiling to define a potential molecular signature or gene expression pattern that may&#xD;
      predict response to dasatinib.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 3, 2008</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 24, 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of dasatinib (Phase I)</measure>
    <time_frame>28 days after start of course 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as measured by NCI CTCAE v3.0 (Phase I)</measure>
    <time_frame>28 days after start of course 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival at 1 year in patients with relapsed sarcoma (Phase II, Stratum A)</measure>
    <time_frame>1 year after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate prior to consolidation therapy as measured by RECIST criteria (Phase II)</measure>
    <time_frame>Prior to consolidation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (Phase II)</measure>
    <time_frame>18 months after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory correlative studies</measure>
    <time_frame>Day 14-21 of dasatinib treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">143</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Childhood Germ Cell Tumor</condition>
  <condition>Extragonadal Germ Cell Tumor</condition>
  <condition>Kidney Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Dasatinib with Ifosfamide, Carboplatin, Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Dasatinib with Ifosfamide, Carboplatin, Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <arm_group_label>Dasatinib with Ifosfamide, Carboplatin, Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide phosphate</intervention_name>
    <arm_group_label>Dasatinib with Ifosfamide, Carboplatin, Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <arm_group_label>Dasatinib with Ifosfamide, Carboplatin, Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
    <arm_group_label>Dasatinib with Ifosfamide, Carboplatin, Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
    <arm_group_label>Dasatinib with Ifosfamide, Carboplatin, Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>Dasatinib with Ifosfamide, Carboplatin, Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Dasatinib with Ifosfamide, Carboplatin, Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Dasatinib with Ifosfamide, Carboplatin, Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Dasatinib with Ifosfamide, Carboplatin, Etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant solid tumor that did not respond to or relapsed&#xD;
             after standard first-line chemotherapy or other antineoplastic therapy (if the&#xD;
             standard therapy for the tumor is generally recognized to be beneficial)&#xD;
&#xD;
               -  Must have been initially diagnosed with malignancy prior to 25 years of age&#xD;
&#xD;
               -  Radiographic, nuclear image, or biopsy confirmation of disease within the past 4&#xD;
                  weeks&#xD;
&#xD;
          -  Meets one of the following criteria:&#xD;
&#xD;
               -  Phase I: Relapsed/refractory malignant solid tumor (excluding CNS tumors)&#xD;
&#xD;
                    -  Patients with recurrent or metastatic disease that was completely resected&#xD;
                       just prior to study entry are eligible&#xD;
&#xD;
               -  Phase II: Patients are stratified according to one of the following diagnoses:&#xD;
&#xD;
                    -  Stratum A: Relapsed sarcoma (rhabdomyosarcoma, osteosarcoma, or Ewing&#xD;
                       sarcoma)&#xD;
&#xD;
                    -  Stratum B: Other relapsed solid tumors, including any of the following:&#xD;
&#xD;
                         -  Other soft tissue sarcomas&#xD;
&#xD;
                         -  Kidney tumors&#xD;
&#xD;
                         -  Lymphoma&#xD;
&#xD;
                         -  CNS tumors*&#xD;
&#xD;
                         -  Other solid tumors (neuroblastoma, gonadal and germ cell tumors, liver&#xD;
                            tumors, or miscellaneous tumors)&#xD;
&#xD;
                    -  Stratum C: Newly diagnosed, poor-risk metastatic sarcoma consisting of&#xD;
                       unresectable pulmonary metastases (≥ 6 nodules) and/or disease involving&#xD;
                       multiple bones or other organs NOTE: *Patients with recurrent primary CNS&#xD;
                       tumors are eligible for the phase II portion of this study provided there&#xD;
                       are no significant intratumoral bleeding toxicities seen in either COG&#xD;
                       pediatric phase I studies of dasatinib or the phase I portion of this study&#xD;
&#xD;
          -  Radiographically measurable disease (Phase II)&#xD;
&#xD;
               -  Measurable disease is not required for patients who are enrolled in the phase I&#xD;
                  portion of this study&#xD;
&#xD;
          -  No bone marrow involvement (Phase I)&#xD;
&#xD;
               -  Patients with bone marrow involvement are eligible for the phase II portion of&#xD;
                  this study provided they are not known to be refractory to red cell or platelet&#xD;
                  transfusions&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Lansky performance status (PS) 50-100% (patients 1-16 years of age) or Karnofsky PS&#xD;
             50-100% (patients &gt; 16 years of age)&#xD;
&#xD;
          -  Life expectancy ≥ 8 weeks&#xD;
&#xD;
          -  ANC &gt; 1,000/μL&#xD;
&#xD;
          -  Platelet count &gt; 75,000/μL&#xD;
&#xD;
          -  Creatinine clearance or GFR ≥ 70 mL/min OR creatinine &lt; 1.5 times upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN for age&#xD;
&#xD;
          -  SGOT or SGPT &lt; 2.5 times ULN for age (&lt; 5 times ULN if liver involvement by tumor)&#xD;
&#xD;
          -  Ejection fraction normal by MUGA OR shortening fraction &gt; 28%&#xD;
&#xD;
          -  No evidence of cardiac arrhythmias requiring therapy&#xD;
&#xD;
          -  Corrected QTc interval &lt; 450 msecs&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to comply with the safety monitoring requirements of this study&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No swallowing dysfunction that would preclude oral medication intake&#xD;
&#xD;
               -  Gastric or jejunal tube allowed provided it is functioning&#xD;
&#xD;
          -  No history of significant bleeding disorder unrelated to cancer, including the&#xD;
             following:&#xD;
&#xD;
               -  Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)&#xD;
&#xD;
               -  Acquired bleeding disorder diagnosed within the past year (e.g., acquired&#xD;
                  anti-factor VIII antibodies)&#xD;
&#xD;
               -  Ongoing or recent (within the past 3 months) significant gastrointestinal&#xD;
                  bleeding&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 7 days since prior and no concurrent drugs known to cause Torsades de&#xD;
             Pointes, including the following:&#xD;
&#xD;
               -  Procainamide or disopyramide&#xD;
&#xD;
               -  Amiodarone, sotalol, ibutilide, or dofetilide&#xD;
&#xD;
               -  Erythromycin or clarithromycin&#xD;
&#xD;
               -  Chlorpromazine, haloperidol, mesoridazine, or thioridazine&#xD;
&#xD;
               -  Bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine,&#xD;
                  levomethadyl, pentamidine, sparfloxacin, or lidoflazine&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosourea-containing therapy)&#xD;
&#xD;
          -  At least 3 months since prior ifosfamide, carboplatin, and/or etoposide phosphate in&#xD;
             the exact combination and dosage as administered in this study&#xD;
&#xD;
          -  More than 7 days since prior filgrastim (G-CSF), sargramostim (GM-CSF), or&#xD;
             interleukin-11&#xD;
&#xD;
          -  More than 14 days since prior pegfilgrastim&#xD;
&#xD;
          -  More than 30 days since prior epoetin alfa&#xD;
&#xD;
          -  No prior cranial-spinal irradiation at doses &gt; 2,400 cGy&#xD;
&#xD;
          -  No prior radiotherapy, including total-body irradiation, to &gt; 50% of the bone marrow&#xD;
             space&#xD;
&#xD;
          -  No other concurrent investigational drugs or anticancer agents&#xD;
&#xD;
          -  No concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital,&#xD;
             felbamate, primdone, oxcarbazepine, or carbamazepine)&#xD;
&#xD;
          -  No concurrent anti-thrombotic or anti-platelet agents (e.g., warfarin, heparin, low&#xD;
             molecular weight heparin, aspirin, ibuprofen, or other NSAIDs)&#xD;
&#xD;
          -  No concurrent CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, or voriconazole)&#xD;
&#xD;
          -  No concurrent highly active antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent St. John's wort&#xD;
&#xD;
          -  No IV bisphosphonates during the first 8 weeks of dasatinib therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith K. Sato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2008</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>childhood extracranial germ cell tumor</keyword>
  <keyword>childhood malignant ovarian germ cell tumor</keyword>
  <keyword>childhood malignant testicular germ cell tumor</keyword>
  <keyword>childhood teratoma</keyword>
  <keyword>clear cell sarcoma of the kidney</keyword>
  <keyword>childhood renal cell carcinoma</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>congenital mesoblastic nephroma</keyword>
  <keyword>cystic nephroma</keyword>
  <keyword>peripheral primitive neuroectodermal tumor of the kidney</keyword>
  <keyword>rhabdoid tumor of the kidney</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>recurrent childhood liver cancer</keyword>
  <keyword>stage IV childhood liver cancer</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
  <keyword>childhood central nervous system choriocarcinoma</keyword>
  <keyword>childhood central nervous system embryonal tumor</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood central nervous system germinoma</keyword>
  <keyword>childhood central nervous system mixed germ cell tumor</keyword>
  <keyword>childhood central nervous system teratoma</keyword>
  <keyword>childhood central nervous system yolk sac tumor</keyword>
  <keyword>recurrent childhood central nervous system embryonal tumor</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood ependymoblastoma</keyword>
  <keyword>childhood medulloepithelioma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>childhood pineal parenchymal tumor</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>childhood high-grade cerebellar astrocytoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood low-grade cerebellar astrocytoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>primary central nervous system Hodgkin lymphoma</keyword>
  <keyword>childhood extragonadal germ cell tumor</keyword>
  <keyword>recurrent childhood malignant germ cell tumor</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>recurrent childhood spinal cord neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 11, 2021</submitted>
    <returned>June 3, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

